Manal F. Abdelmalek

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Mary E. Rinella, Jeffrey V. Lazarus, Vlad Ratziu et al. · Hepatology · 2023 · 2.5K citations · Full text

Evidence-based Medicine, Pathology, Fatty Liver Disease +16

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

Brent A. Neuschwander‐Tetri, Rohit Loomba, Arun J. Sanyal et al. · The Lancet · 2014 · 2.2K citations

Hepatology, Medicine, Liver Physiology +7

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease

Mary E. Rinella, Brent A. Neuschwander‐Tetri, Mohammad Shadab Siddiqui et al. · Hepatology · 2023 · 2K citations · Full text

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

Stephen A. Harrison, Pierre Bédossa, Cynthia D. Guy et al. · New England Journal of Medicine · 2024 · 1.4K citations · Full text

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Interim Analysis, Metabolic Associated Steatohepatitis, Hepatology +7